Intriguingly, our findings indicate that pharmacological PARP-1 inhibition and NAD+ boosting compounds hold promise as novel therapeutic agents for SGS, which to date has no cure. The gene discussed is PARP1; the disease is Schinzel-Giedion syndrome.